Gwathmey Preclinical Testing Services, Inc. launched a Cardionomics services and formed a Cardionomics Advisory Board to provide new methods and technologies to improve cardiac safety of drug candidates.
Cardiac toxicity has played a major role in shutting down the sales of major drugs over the past 30 years. It is estimated that 28 percent of major drugs had to be withdrawn in that period due to cardiac side effects.
Features of Gwathmey Preclinical’s Cardionomics Services include: cardiac catheterization, pressure-volume determinations, isolated perfused hearts, telemetry, echocardiography, electrocardiography, isolated cardiac myocytes with calcium imaging (animal and human), isolated muscle studies (animal and human), human heart failure tissue cDNA array for human pharmacogenomics and toxicogenomics.
In addition, the company has assembled a physician and researcher advisory board for its Cardionomics Services.
Gwathmey Preclinical Testing Services, Inc. supports biotechnology and pharmaceutical companies to meet their scientific and financial goals through a disciplined approach that maximizes quality, throughput and process efficiency.
Release date: May 9, 2008
Source: Gwathmey, Inc.
Filed Under: Drug Discovery
